COMPARISON
Cagrilintide vs Tirzepatide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Cagrilintide is authorised or registered in 0 and Tirzepatide in 10 of the 10 registers read. Cagrilintide: highest phase Phase 3 (17 phase 3 trials, 0 with posted results). Tirzepatide: highest phase Phase 4 (after approval). 4 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Cagrilintide | Tirzepatide | |
|---|---|---|
| Registered trials differs | 66 clinicaltrials.gov · 2026-10-03 | 309 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | Not checked no record of "fdaLabel" for cagrilintide | FDA-approved: MOUNJARO openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for cagrilintide | 2022-09-15 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for cagrilintide | A10BX16 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Cagrilintide | placebo | Tirzepatide | placebo |
|---|---|---|---|---|
| Nausea | 29.0% | 14.8% | 25.6% | 8.1% |
| COVID-19 | 16.1% | 13.1% | 15.5% | 16.0% |
| Constipation | 16.1% | 13.1% | 13.7% | 4.5% |
| Diarrhoea | 16.1% | 6.6% | 21.2% | 8.3% |
| Vomiting | 9.7% | 1.6% | 11.4% | 2.6% |
| Fatigue | 9.7% | 1.6% | - | - |
| Gastrooesophageal reflux disease | 9.7% | 1.6% | - | - |
| Back pain | 6.5% | 3.3% | - | - |
| Eructation | 6.5% | 0.0% | - | - |
| Gastroenteritis | 6.5% | 6.6% | - | - |
| Decreased appetite | - | - | 11.6% | 2.9% |
| Dyspepsia | - | - | 7.9% | 2.7% |
| Headache | - | - | 6.6% | 6.2% |
| Abdominal pain | - | - | 6.0% | 2.7% |
| Upper respiratory tract infection | - | - | 5.7% | 6.2% |
Trial register Cagrilintide: 1 placebo-controlled trials; Tirzepatide: 19. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Cagrilintide side effects · Tirzepatide side effects
LEGAL STATUS
Approval in each country read
| Country | Cagrilintide | Tirzepatide | Register |
|---|---|---|---|
| United States | Not on the register | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Not on the register | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
4 registered trials include both
| NCT06534411 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGL COMPLETED · updated 2026-09-09 |
|---|---|
| NCT06221969 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With COMPLETED · updated 2026-09-04 |
| 2023-509600-15-00 | Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in parti Not stated · updated 2026-08-03 |
| NCT06131437 | A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight COMPLETED · updated 2026-02-06 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.